Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hLF1-11 safety study in autologous HSCT recipients
NL-OMON20231Active, not recruiting
- Sponsor
- AM-Pharma
- Start
- Mar 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of human lactoferrin peptide 1-11 in bacterial disease and mycoses, sponsored by AM-Pharma. Primary endpoint: Safety and tolerability. Started Mar 2006; status: active, not recruiting.
02
Drugs
human lactoferrin peptide 1-11
03
Conditions
bacterial diseasemycoses
Beyond the preview
Go deeper on NL-OMON20231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20231.